Logo image of SPRB

SPRUCE BIOSCIENCES INC (SPRB) Stock Fundamental Analysis

USA - NASDAQ:SPRB - US85209E2081 - Common Stock

125 USD
+5.71 (+4.79%)
Last: 11/7/2025, 1:47:49 PM
Fundamental Rating

2

Overall SPRB gets a fundamental rating of 2 out of 10. We evaluated SPRB against 534 industry peers in the Biotechnology industry. The financial health of SPRB is average, but there are quite some concerns on its profitability. SPRB is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

SPRB had negative earnings in the past year.
In the past year SPRB has reported a negative cash flow from operations.
SPRB had negative earnings in each of the past 5 years.
SPRB had a negative operating cash flow in each of the past 5 years.
SPRB Yearly Net Income VS EBIT VS OCF VS FCFSPRB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

SPRB has a Return On Assets of -221.53%. This is amonst the worse of the industry: SPRB underperforms 91.57% of its industry peers.
SPRB has a worse Return On Equity (-366.75%) than 74.16% of its industry peers.
Industry RankSector Rank
ROA -221.53%
ROE -366.75%
ROIC N/A
ROA(3y)-72.45%
ROA(5y)-53.79%
ROE(3y)-104.69%
ROE(5y)-74.36%
ROIC(3y)N/A
ROIC(5y)N/A
SPRB Yearly ROA, ROE, ROICSPRB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SPRB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SPRB Yearly Profit, Operating, Gross MarginsSPRB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800 -1K

More info and screens

5

2. Health

2.1 Basic Checks

SPRB does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SPRB has more shares outstanding
SPRB has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, SPRB has a worse debt to assets ratio.
SPRB Yearly Shares OutstandingSPRB Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 100K 200K 300K 400K 500K
SPRB Yearly Total Debt VS Total AssetsSPRB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

SPRB has an Altman-Z score of -19.35. This is a bad value and indicates that SPRB is not financially healthy and even has some risk of bankruptcy.
SPRB has a worse Altman-Z score (-19.35) than 84.27% of its industry peers.
There is no outstanding debt for SPRB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -19.35
ROIC/WACCN/A
WACC8.74%
SPRB Yearly LT Debt VS Equity VS FCFSPRB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 2.60 indicates that SPRB has no problem at all paying its short term obligations.
With a Current ratio value of 2.60, SPRB is not doing good in the industry: 68.73% of the companies in the same industry are doing better.
A Quick Ratio of 2.60 indicates that SPRB has no problem at all paying its short term obligations.
SPRB has a worse Quick ratio (2.60) than 66.85% of its industry peers.
Industry RankSector Rank
Current Ratio 2.6
Quick Ratio 2.6
SPRB Yearly Current Assets VS Current LiabilitesSPRB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

SPRB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -396.54%.
Looking at the last year, SPRB shows a very negative growth in Revenue. The Revenue has decreased by -86.42% in the last year.
EPS 1Y (TTM)-396.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%78.79%
Revenue 1Y (TTM)-86.42%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

The Earnings Per Share is expected to grow by 14.85% on average over the next years. This is quite good.
The Revenue is expected to decrease by -14.87% on average over the next years. This is quite bad
EPS Next Y13.62%
EPS Next 2Y35.9%
EPS Next 3Y22.92%
EPS Next 5Y14.85%
Revenue Next Year-80.37%
Revenue Next 2Y-41.42%
Revenue Next 3Y1.34%
Revenue Next 5Y-14.87%

3.3 Evolution

SPRB Yearly Revenue VS EstimatesSPRB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2027 2028 2030 2031 2032 50M 100M
SPRB Yearly EPS VS EstimatesSPRB Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -50 -100 -150

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

SPRB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SPRB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SPRB Price Earnings VS Forward Price EarningsSPRB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SPRB Per share dataSPRB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 -40 -60 -80

4.3 Compensation for Growth

A more expensive valuation may be justified as SPRB's earnings are expected to grow with 22.92% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.9%
EPS Next 3Y22.92%

More info and screens

0

5. Dividend

5.1 Amount

SPRB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SPRUCE BIOSCIENCES INC

NASDAQ:SPRB (11/7/2025, 1:47:49 PM)

125

+5.71 (+4.79%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14 2025-08-14/amc
Earnings (Next)11-10 2025-11-10/amc
Inst Owners21.05%
Inst Owner Change-58.5%
Ins Owners2.32%
Ins Owner Change0.06%
Market Cap70.00M
Revenue(TTM)1.30M
Net Income(TTM)-48.34M
Analysts43.33
Price Target6.4 (-94.88%)
Short Float %3.73%
Short Ratio0.01
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)17.93%
Min EPS beat(2)-46.19%
Max EPS beat(2)82.06%
EPS beat(4)2
Avg EPS beat(4)-29.23%
Min EPS beat(4)-166.11%
Max EPS beat(4)82.06%
EPS beat(8)6
Avg EPS beat(8)-2.9%
EPS beat(12)9
Avg EPS beat(12)1.14%
EPS beat(16)12
Avg EPS beat(16)3.55%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)0
Avg Revenue beat(4)-70.82%
Min Revenue beat(4)-100%
Max Revenue beat(4)-22.79%
Revenue beat(8)4
Avg Revenue beat(8)-0.65%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-37.3%
PT rev (3m)318%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-10103.3%
EPS NY rev (1m)0%
EPS NY rev (3m)-11084.2%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-37.5%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 53.89
P/FCF N/A
P/OCF N/A
P/B 5.31
P/tB 5.31
EV/EBITDA N/A
EPS(TTM)-86
EYN/A
EPS(NY)-11.54
Fwd EYN/A
FCF(TTM)-91.88
FCFYN/A
OCF(TTM)-91.88
OCFYN/A
SpS2.32
BVpS23.54
TBVpS23.54
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -221.53%
ROE -366.75%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-72.45%
ROA(5y)-53.79%
ROE(3y)-104.69%
ROE(5y)-74.36%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.6
Quick Ratio 2.6
Altman-Z -19.35
F-Score1
WACC8.74%
ROIC/WACCN/A
Cap/Depr(3y)8.1%
Cap/Depr(5y)65.57%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-396.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%78.79%
EPS Next Y13.62%
EPS Next 2Y35.9%
EPS Next 3Y22.92%
EPS Next 5Y14.85%
Revenue 1Y (TTM)-86.42%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-80.37%
Revenue Next 2Y-41.42%
Revenue Next 3Y1.34%
Revenue Next 5Y-14.87%
EBIT growth 1Y-6.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-114.46%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-70.89%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-70.89%
OCF growth 3YN/A
OCF growth 5YN/A

SPRUCE BIOSCIENCES INC / SPRB FAQ

Can you provide the ChartMill fundamental rating for SPRUCE BIOSCIENCES INC?

ChartMill assigns a fundamental rating of 2 / 10 to SPRB.


What is the valuation status for SPRB stock?

ChartMill assigns a valuation rating of 1 / 10 to SPRUCE BIOSCIENCES INC (SPRB). This can be considered as Overvalued.


What is the profitability of SPRB stock?

SPRUCE BIOSCIENCES INC (SPRB) has a profitability rating of 0 / 10.


How financially healthy is SPRUCE BIOSCIENCES INC?

The financial health rating of SPRUCE BIOSCIENCES INC (SPRB) is 5 / 10.


What is the expected EPS growth for SPRUCE BIOSCIENCES INC (SPRB) stock?

The Earnings per Share (EPS) of SPRUCE BIOSCIENCES INC (SPRB) is expected to grow by 13.62% in the next year.